2. Anti-infection
  3. Flavivirus

Flavivirus

Flavivirus is a group of single-stranded positive-sense RNA viruses that are mainly transmitted by arthropods such as mosquitoes and ticks. The viral particles of the Flavivirus are spherical, with a diameter of approximately 40-60 nanometers and have an envelope. The envelope is embedded with spike glycoproteins, which play a crucial role in the recognition and binding process between the virus and host cells. Flavivirus contains a variety of viruses, such as the yellow fever virus and the dengue virus, etc., which can cause a variety of serious diseases and have a significant impact on global public health security[1].

Flavivirus Related Products (131):

Cat. No. Product Name Effect Purity
  • HY-B0421
    Mycophenolic acid Inhibitor 99.87%
    Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 µM. Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid is an immunosuppressive agent. Antiangiogenic and antitumor effects[1][2].
  • HY-15310
    Ivermectin
    Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X4 and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import[1][2][3][4]. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19[5].
  • HY-10396
    Emricasan Inhibitor 99.59%
    Emricasan (PF 03491390) is an orally active and irreversible pan-caspase inhibitor. Emricasan inhibits Zika virus (ZIKV)-induced increases in caspase-3 activity and protected human cortical neural progenitors[1].
  • HY-107433
    U18666A
    U18666A, an intra-cellular cholesterol transport inhibitor, inhibits replication of Ebola virus, dengue virus, and human hepatitis C virus[1].
  • HY-108462
    ML-SA1 Inhibitor 99.33%
    ML-SA1, as a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity. The IC50 value of ML-SA1 against DENV2 RNA and ZIKV RNA is 8.3 μM and 52.99 μM, respectively. ML-SA1 induces autophagy. ML-SA1 can be used for the research of broad-spectrum antiviral[1].
  • HY-169429
    CHIKV-IN-5 Inhibitor
    CHIKV-IN-5 (Compound 26) is a CHIKV inhibitor (EC90 = 0.45 μM). CHIKV-IN-5 inhibits CHIKV replication at a late stage in the virus life cycle by blocking structural protein translation. CHIKV-IN-5 has great in vitro mouse microsomal stability. CHIKV-IN-5 reduces footpad swelling and decreases virus dissemination to other tissues in mice infected with CHIKV[1].
  • HY-100528R
    Nanchangmycin (Standard) Inhibitor
  • HY-100528AR
    Dianemycin (Standard) Inhibitor
    4-Methoxycinnamic acid (Standard) is the analytical standard of 4-Methoxycinnamic acid. This product is intended for research and analytical applications. 4-Methoxycinnamic acid is detected as natural phenylpropanoid in A. preissii.
  • HY-N3942
    Glabranine Inhibitor
    Glabranine, an flavonoid, is isolated from Tephrosia s.p, exerts a inhibitory effect in vitro on the dengue virus[1]. Glabranine forms interaction with the soluble ectodomain of DENV type 2 (DENV2) E protein[2].
  • HY-150600
    NS2B/NS3-IN-7 Inhibitor
    NS2B/NS3-IN-7 (compound 26) is a highly potent Zika virus NS2B-NS3 protease inhibitor with a Ki value of 2.33 nM. NS2B/NS3-IN-7 can reduce amounts of ZIKV-infected cells[1].
  • HY-155053
    ZIKV-IN-6 Inhibitor
    ZIKV-IN-6 (compound 22) is an inhibitor of Zika virus (ZIKV), with low cytotoxicity (CC50＞50 μM). ZIKV-IN-6 binds to ZIKV RdRp directly and inhibits viral RNA synthesis by ZIKV NS5. ZIKV-IN-6 suppresses the excessive inflammatory response and pyroptosis[1].
  • HY-B0421S2
    Mycophenolic acid-13C17 Inhibitor
    Mycophenolic acid-13C17 (Mycophenolate-13C17) is the 13C labeled Mycophenolic acid (HY-B0421). Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 μM. Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid is an immunosuppressive agent. Antiangiogenic and antitumor effects.
  • HY-N12710
    Crenatoside Inhibitor
    Crenatoside is a phenylethanol glycoside compound that can be isolated from the ethyl acetate of the tree extract of T. stans var. stans with EC50 value of 34.78 μM. Crenatoside has anti-Zika virus activity[1].
  • HY-134665
    NITD-2 99.36%
    NITD-2, a dengue virus (DENV) polymerase inhibitor, inhibits the DENV RdRp-mediated RNA elongation. NITD-2 penetrates cell membrane poorly[1].
  • HY-100540B
    Golgicide A-2 99.53%
    Golgicide A-2 (GCA-2), a Golgicide A (GCA) derivative, is the most active enantiomer of GCA. Golgicide A-2 displays high selectivity and efficiency in killing An. stephensi larvae and can be used for the research of dengue virus related diseases[1].
  • HY-N0838
    Cephalotaxine
    Cephalotaxlen ((-)-Cephalotaxine) is an alkaloid that can be isolated from Cephalotaxus fortunei, with antileukemic and antiviral activities. Cephalotaxlen has anti-ZIKV (Zika virus) activity[1][2][3].
  • HY-19961
    KIN1408 99.55%
    KIN1408 is an agonist of the RIG-1-like receptor (RLR) pathway and exhibits a broad-spectrum antiviral activity. KIN1408 exhibits activity against HCV, influenza A, dengue virus 2, Ebola, Nipah, and Lassa viruses[1][2].
  • HY-13986
    Merimepodib 99.27%
    Merimepodib (VX-497) is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.
  • HY-139602
    (+)-JNJ-A07
    (+)-JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. (+)-JNJ-A07 exerts nanomolar to picomolar activity against a panel of 21 clinical isolates. (+)-JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models[1].
  • HY-124662
    IHVR-19029
    IHVR-19029 is a potent endoplasmic reticulum (ER) α-glucosidases I and II inhibitor, with an IC50 of 0.48 μM for ER a-glucosidase I. IHVR-19029 efficiently blocks the replication of several hemorrhagic fever viruses, such as Dengue virus (DENV), Ebola virus (EBOV) and Rift Valley fever virus. The combination of IHVR-19029 with Favipiravir (HY-14768) improves the antiviral efficacy[1][2][3][4].